We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Ligand Pharmaceuticals Incorporated (PK) | USOTC:LGNZZ | OTCMarkets | Right |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.109 | 0.10 | 0.13 | 0.00 | 13:00:57 |
Delaware
|
001-33093
|
77-0160744
|
(State or other jurisdiction of
|
(Commission File Number)
|
(I.R.S. Employer
|
incorporation or organization)
|
|
Identification No.)
|
3911 Sorrento Valley Boulevard, Suite 110
|
|
|
San Diego
|
|
|
CA
|
|
92121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
LGND
|
The Nasdaq Global Market
|
|
LIGAND PHARMACEUTICALS INCORPORATED
|
Date: January 10, 2020
|
By: /s/ Charles Berkman
Name:Charles Berkman
Title: Senior Vice President, General Counsel and Secretary
|
1 Year Ligand Pharmaceuticals (PK) Chart |
1 Month Ligand Pharmaceuticals (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions